论文部分内容阅读
众所周知,患有MYC/BCL2双重打击性淋巴瘤(DHL)的患者临床进展迅速,对包括强化化疗和干细胞移植等在内的各种治疗反应均较差。但目前对伴MYC重排而不伴Bcl-2和Bcl-6重排的高级别B细胞性淋巴瘤(即单一打击性淋巴瘤,SHL)了解较少。本研究中,作者对61例SHL进行评估,并与83例DHL进行比较,所有病例均行MYC、Bcl-2和Bcl-6荧光原位杂交检测证实。尽管SHL和DHL患者之间的临床病理特点
It is well-known that patients with MYC / BCL2 double-hit lymphoma (DHL) undergo rapid clinical progress and respond poorly to various therapies, including intensive chemotherapy and stem cell transplantation. However, there is currently little knowledge of high-grade B-cell lymphoma (ie, single-hit lymphoma, SHL) with MYC rearrangements without Bcl-2 and Bcl-6 rearrangements. In this study, 61 SHL patients were evaluated and compared with 83 DHLs. MYC was performed in all cases, and Bcl-2 and Bcl-6 fluorescence in situ hybridization tests were performed. Despite the clinicopathological features between SHL and DHL patients